Post-market clinical safety trials have indicated that medications containing both long-acting beta agonists (LABAs) and inhaled corticosteroids (ICSs) do not result in more serious asthma-related outcomes than treatment with ICSs alone…
Biosimilar SB2 May Work as Well as Infliximab for Rheumatoid Arthritis
In a 78-week study examining the interchangeability of infliximab with the biosimilar SB2, the treatments demonstrated long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis. Across all the study’s treatment groups, patients had similar treatment response rates, and the long-term clinical profile of SB2 was comparable with infliximab…
Neurontin Prescriptions Surge Amid Opioid Crisis
(Reuters Health)—Prescriptions for nerve pain medicines like Neurontin and Lyrica have more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests. The proportion of U.S. adults prescribed Neurontin and other drugs in the same family of medicines climbed from 1.2% in…
New Drug Approvals Hit 21-Year High in 2017
LONDON (Reuters)—U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light—more than double the previous year—while the figure also rose in the European Union. The European Union (EU) recommended 92 new drugs, including generics, up from 81; and China laid out plans to speed up approvals in what…
Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA
In the U.S., a new formulation and an ergonomic delivery system for single doses of etanercept are now available for RA patients…
Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
Bisphosphonate Drug Holidays Drug holidays are common for patients on bisphosphonate therapy. Often, these breaks in treatment are related to known U.S. Food and Drug Administration (FDA) warnings and drug class adverse effects. Currently, data on fracture risk related to drug holidays are limited. In recent research highlighted at the 2017 ACR/ARHP Annual Meeting ,…
E6011 Safe & Well Tolerated in RA Patients
E6011, an anti-fractalkine monoclonal antibody, proved promising for the treatment of rheumatoid arthritis during a 52-week clinical trial…
Tocilizumab Monotherapy May Sustain Low Disease Activity in RA Patients
New research demonstrates that subcutaneous tocilizumab monotherapy may preserve disease control in RA patients who have discontinued methotrexate…
Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
(Reuters)—The U.S. Food and Drug Administration approved Pfizer Inc’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer’s Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn’s disease and skin disorder plaque psoriasis, the drugmaker said. Biosimilars are medicines deemed…
Vitamin D-Metabolite Ratio Predicts Fracture Risk Better than 25(OH)D
NEW YORK (Reuters Health)—Vitamin D-metabolite ratio (VMR) may be a better marker of bone health than 25(OH)D (25-hydroxyvitamin D), a new study suggests. “The parameter that’s currently used to assess vitamin D status, 25(OH)D, is a flawed measure because it doesn’t consistently associate with important bone outcomes like hip fractures,” Dr. Charles Ginsberg of Veterans…
- « Previous Page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- …
- 122
- Next Page »